Cidara Therapeutics skyrockets 1,165% after positive CD388 data and Merck's acquisition bid. Read why CDTX stock is a Hold.

Merck (MRK) stock achieved a 5-day winning streak, with total gains during this time reaching 6.9%. The company’s market ...

Merck (MRK) stock rose about 4% on Monday, as of writing, after top Wells Fargo analyst Mohit Bansal upgraded his rating for the pharma company to Buy from Hold. Bansal increased the price target for ...

Merck spent a small fortune on the acquisition of Acceleron Pharma, and so far, it's paying off. Recent phase 2 data suggests the pharmaceutical giant could get even more bang for its buck. Despite ...

Merck MRK announced that the phase II CADENCE study, which evaluated its newly launched pulmonary arterial hypertension (“PAH”) drug Winrevair, for treating adults with combined post and precapillary ...

Merck & Co. is undervalued, trading at lower multiples than peers, due to concerns over patent expirations and recent financial volatility. Despite modest overall revenue growth, oncology—especially ...

Positive developments in the late-stage trials for Merck’s Keytruda immunotherapy lung cancer treatment led the company’s stock to spike nearly 4 percent April 9, according to Fortune. The KEYNOTE-o42 ...

Exelixis, Inc. (EXEL) is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat ...

Merck (NYSE:MRK) operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The 52-week range of Merck stock price was $75.93 to $134.63. Merck's ...